| | FORCE developed our XRAY-Behind the Headlines program to help people separate relevant cancer news from hype by providing honest evaluations of cancer research reported in the media. Originally developed for young breast cancer survivors, we now have XRAY portals focused on Metastatic Breast Cancer and Ovarian Cancer. Soon we will be adding Prostate Cancer and Pancreatic Cancer portals. The XRAY Quarterly Digest provides a compilation of XRAY reviews published over the last three months. |
Headlines Exaggerate Claims About a New Breast Cancer Vaccine Did you see the headlines on a new breast cancer vaccine? Can a simple shot cure or prevent early-stage breast cancer? Read behind the headlines in our XRAY review on the promising outcome of a Florida woman who was the first to enroll in an early breast cancer vaccine trial.
Read the Article
|
Should Women With Metastatic Breast Cancer Have Genetic Testing for an Inherited Mutation? Recent research shows that a significant number of patients with metastatic breast cancer have an inherited mutation in a gene associated with hereditary breast cancer. This finding is relevant for people with metastatic breast cancer who may benefit from targeted therapy based on their genetic test results.
Read the Review
|
Study on PARP Inhibitors After Front-line Ovarian Cancer Treatment Showed Benefit in Women With or Without a BRCA Mutation
This study looked at the effectiveness and safety of the PARP inhibitor niraparib, as maintenance therapy in newly-diagnosed ovarian cancer patients who had a response to chemotherapy.
Read the Review
| The FDA Issues Warning on a Rare, Serious Side Effect from CDK Inhibitors
The U.S. Food and Drug Administration issued a safety alert for people prescribed CDK4/6 inhibitors.
Read the Review
|
Is it Safe for BRCA Mutation Carriers to Become Pregnant Following Breast Cancer?
New research shows that pregnancy after breast cancer is safe for women with BRCA mutations and their babies.
Read the Review
| Can PARP Inhibitors Benefit People With Early-Stage Breast Cancer?
PARP inhibitors have been approved for treatment of advanced or metastatic breast cancer for patients with BRCA mutations. An early study showed that the majority of patients who took the PARP inhibitor talazoparib alone before surgery had effective treatment and manageable side effects. Expanded clinical trials are in progress to verify this result.
Read the Review |
|
|
|
| |
